208

into type I, which contained a higher pro- portion of GO Gl-phase cells, and type II, which contained a higher Dropor- tion of S, Ggm-phase cells. The medi-

an survival times for the patients with limited disease of type I, type II and the patients with extensive disease of type I, type II were 17.2 months, 10.2 months, i0.0 months, and 5.6 months, respective- ly. Patients with limited disease of type I had a significantly longer survival time than patients with limited disease of type II. A distinct correlation was found between the histogram pattern and the survival of the patients. These results indicated that the nuclear DNA histogram pattern may be an indicator to allow speculation as to the prognosis of patients with small cell carcinoma of the lung.

Prognostic Significance of DNA Patterns and Resistance-Predictive Tests in Non- Small Cell Lung Carcinoma. Volm, M., Drings, P., Mattern, J. et al. German Cancer Research Center, Department of Experimental Pathology, D-6900 Heidel- berg, Germany. Cancer 56: 1396-1403, 1985.

In a cooperative study. 240 surgical specimens of patients with non-small cell lung carcinomas (NSCLC) were investigated by means of flow cytometry, xenotransplan- tation to athymic mice and, an in vitro short-term test for predicting resistance. Aneuploidy was found in 83% of the tumors, and 20% showed more than one aneuploid DNA stemline. Patients with both aneuploid tumors and tumors with more than one DNA stemline had a significantly shorter sur- vival rate than those with only diploid or only one DNA stemline. Patients whose tumors showed a low GO/Gl-cell proportion or a high proliferation pool (S and G2/M-cell proportion) died earlier. A re- lationship could not be discerned between growth of tumors in nude mice or estab- lishment of cell lines and the prognosis for the patients. Patients with in vitro- resistant tumors died earlier under chemo- therapy than those with in vitro-sensiti- ve tumors. Patients treated by radiation survived longer if the tumors were resi- stant in vitro. Thus, DNA patterns and in vitro short-term tests for predicting resistance represent useful tools for prognostic evaluation of patients with NSCLC.

Phagocytic Activity of Alveolar ~'~cropha- ges in Patients with Bronchogenic Carci- noma. Gangemi, J.D., Olsen, G.N., Fechter, C. et al. Department of Microbiology, Univer- sity of South Carolina School of Medicine,

Wm. Jennings Bryan Dorn Veterans Administration Hospital, Columbia, SC 29208, U.S.A. Cancer Immunol. Immunother. 20: 158-166, 1985.

Human bronchoalveolar cells were obtained by lavage during diagnostic fiberoptic bronchoscopy of 21 patients suspected of having lung malignancies. Of these patients ii were diagnosed as having pri- mary lung cancer (Group I) and included individuals with squamous cell carcinoma, adenocarcinoma, un- differentiated large and oat cell carcinoma at varying locations and TNM stages, 4 patients de- monstrated nonprimary metastatic carcinoma (Group II), and 6 patients did not reveal detectable tumors by bronchoscopy or follow-up (Group III) and were included as study controls. We examined the ability of pulmonary alveolar macrophages (PAMs) lavaged from patients in each of the three study groups to phagocytose opsonized sheep red blood cells. Pha- gocytic activity varied among patients in the same and different study groups; however, no significant differences were observed in the phagocytic or tumoristatic activities of PAMs recovered from tumor- bearing and nontumor-bearing lung regions of the same patient. Moreover, lavage fluids collected from tumor-bearing regions did not suppress the phago- cytic activity cf P~MS collected from contrel lungs nor luJ,g r~,gions contralateral to ~he tumor-bearing lung. The data do not support the view that bron- chial neoplasms or their secreted products suppress phagocytic functions of alveolar macrophages.

Antibody-Dependent Cellular Cytotoxicity in Blood Monocytes and Alveolar Macrophages in Patients with Lung Cancer. McLennan, G., Gill, P.G., De Young, N.J. Department of Thoracic Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, Australia. J. Natl. Cancer Inst. 75: 23-27, 1985.

Antibody-dependent cellular cytotoxicity (ADCC), mediated by blood monocytes (MNC) and pulmonary alveolar macrophages (PAM) obtained from 31 pa- tients with lung cancer and 13 control subjects, was determined. The ADCC of the PAM obtained from patients with lung cancer was significantly less (40% reduction) than that of the control group. This finding was demonstrated over the range of ef- fector-to-target cell ratios. The ADCC of blood MNC from the cancer patients was not different from that of control subjects and in both groups the ADCC of blood MNC was significantly greater than that of lung macrophages. Comparison of PAM ADDC in smokers and nonsmokers within the control group suggested that the lower activity in cancer patients was not simply an effect of smoking.

Association Between Urinary Zinc Excretion and Lym- phocyte Dysfunction in Patients with Lung Cancer. Allen, J.I., Bell, E., Boosalis, M.G. et al. Section of Gastroenterology, Veterans Administration Medical Center, Minneapolis, MN 55417, U.S.A. Am. J. Med. 79: 209-215, 1985.

Patients with bronchogenic carcinoma often have low serum zinc concentrations and sometimes have markedly elevated renal zinc losses. Since normal